Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: GATC Biotech; Eurofins Operon MWG; Progenika; Strand Life Sciences

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GATC Biotech this week said that it intends to analyze 100,000 human genomes within the next four year for pharmaceutical, diagnostic, and academic research customers. The sequencing services provider added that it will open a new business unit for human genome analysis at its headquarters in Germany. GATC said that it will use Illumina's HiSeq 2000 and Pacific Biosciences' RS systems to achieve its goal.

Eurofins MWG Operon this week said that it has added a Roche GS Junior sequencer to its arsenal of instruments used in providing sequencing services. It said the GS Junior is suited for smaller-scale projects that require only one-eighth of the capacity of a GS FLX Titanium run or which would not be suitable for an Illumina run.

Progenika has obtained the CE Mark for its LPLchip, a DNA chip to detect more than 120 mutations in the lipoprotein lipase gene. The test can rapidly diagnose patients with complete and partial lipoprotein lipase deficiency (LPLD), a condition that can lead to serious complications, such as acute recurring pancreatitis. The test was developed in collaboration with Amsterdam Molecular Therapeutics, which has filed for European marketing clearance for its drug Glybera for treating LPLD.

Strand Life Sciences announced this week the creation of a US-based subsidiary called Strand Scientific Intelligence, which will be based in the San Francisco Bay area.